ArriVent Licenses ARR-002 to Allist for Greater China in Deal Worth Up to $80.6M
AVBP sits 95% above its 52-week low of $16.1.
Summary
ArriVent licensed ARR-002 to Allist for Greater China in a deal worth up to $80.6M plus royalties, while reporting Q2 results with cash runway into 2028.
Key Events · M&A and Partnerships · AVBP
-
ARR-002 Licensed to Allist for Greater China
Exclusive license granted to Shanghai Allist for ARR-002 in Greater China, with up to $80.6M in milestone payments and tiered royalties on net sales.
-
Q2 2026 Financial Results
Net loss of $49.9M for Q2 2026; cash and investments of $373.1M as of June 30, 2026, expected to fund operations into 2028.
-
Pipeline Progress
ARR-217 advanced to Phase 1b dose optimization; ARR-002 first patient dosing expected Q3 2026.
-
Upcoming Milestone
Topline data from the global pivotal FURVENT Phase 3 trial for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected in 2H 2026.
Analysis · AVBP · Life Sciences
ArriVent out-licensed its ARR-002 ADC to Shanghai Allist for Greater China, retaining all other global rights. The deal includes up to $80.6 million in milestone payments plus tiered royalties, providing non-dilutive capital while shifting development and commercialization costs in the region to Allist. The company also reported Q2 results with a $49.9 million net loss and $373.1 million in cash, expected to fund operations into 2028.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1528 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVBP was trading at $31.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $16.10 to $35.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.